| Symbol | IMRX |
|---|---|
| Name | IMMUNEERING CORP |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE, MA 02142 |
| Telephone | 617-500-8080 |
| Fax | — |
| — | |
| Website | https://www.immuneering.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001790340 |
| Description | Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The companys proprietary computational Disease Cancelling Technology platform enables Immuneerings drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies. Additional info from NASDAQ: |
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
Read moreImmuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
Read moreNew Form DEFA14A - Immuneering Corp <b>Filed:</b> 2026-04-20 <b>AccNo:</b> 0001790340-26-000050 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - Immuneering Corp <b>Filed:</b> 2026-04-20 <b>AccNo:</b> 0001790340-26-000048 <b>Size:</b> 2 MB
Read moreImmuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
Read moreNeufeld Leah R 🟢 acquired 3.6K shares of Immuneering Corp (IMRX) at $4.29 Transaction Date: Mar 13, 2026 | Filing ID: 000044
Read moreImmuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
Read more(10% Negative) IMMUNEERING CORPORATION (IMRX) Reports Q1 2026 Financial Results
Read moreImmuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Read more